| Literature DB >> 35991609 |
Jiadai Zhai1, Shucheng Li2, Lin Fu2, Chuang Li2, Bingxia Sun2, Feng Sang2, Hongliang Liu2.
Abstract
Clinical infections arise from multidrug-resistant bacteria and pose a serious threat to human and global public health. Moreover, due to very few antibiotics being discovered, there is an urgent need to develop new antibacterial agents to combat antimicrobial resistance challenges. In this study, a series of new chalcone derivatives bearing a 3'-hydroxyisoprenyl moiety were prepared to employ Claisen-Schmidt condensation as a key step by combinatorial chemistry, and overall yields of these novel derivatives are in the range of 28-68% in the two-step reaction. Sanjuanolide and the synthesized derivatives have been investigated for their expected antibacterial activities against Gram-positive bacteria (Staphylococcus aureus CMCC 26003) and Gram-negative bacteria (Escherichia coli CMCC 44102). Among these compounds, only 4c (MIC = 12.5 μg/ml) and 4d (MIC = 25 μg/ml) exhibited antibacterial activity comparable to sanjuanolide (MIC = 12.5 μg/ml, against S. aureus CMCC 26003), and the results of subsequent in vivo experiments on sanjuanolide suggest that sanjuanolide exhibits bacteriostatic and bactericidal effects by altering the cellular structure, disrupting the integrity of cell membranes, and reducing the outer membrane potential.Entities:
Keywords: antibacterial activity; chalcone; derivatives; hydroxyisoprenyl moiety; synthesis
Year: 2022 PMID: 35991609 PMCID: PMC9388722 DOI: 10.3389/fchem.2022.959250
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.545
FIGURE 1Structures of chalcone, curcumin, sanjuanolide, and their new derivatives.
FIGURE 2Synthesis of new chalcone derivatives 4a–4j.
Minimal inhibitory concentration (MIC) of curcumin, sanjuanolide, and its new derivatives (4a–4j).
| Compound |
|
|
|---|---|---|
| Sanjuanolide | 12.5 | >200 |
| Curcumin | >200 | >200 |
|
| >200 | >200 |
|
| 100 | >200 |
|
| 12.5 | >200 |
|
| 25 | >200 |
|
| >200 | >200 |
|
| >200 | >200 |
|
| >200 | >200 |
|
| >200 | >200 |
|
| >200 | >200 |
|
| >200 | >200 |
*MIC (in μg/mL) values. Assay experiments were performed in duplicates at three independent times.
FIGURE 3Antibacterial effect of sanjuanolide determined using the plate counting assay.
FIGURE 4SEM images of S. aureus CMCC 26003 and E. coli CMCC 44102 in the absence of sanjuanolide (A,B) and presence of sanjuanolide (C,D).
FIGURE 5Fluorescence histogram superimposition and mean fluorescence intensity (MFI) of S. aureus CMCC 26003 (A) and E. coli CMCC 44102 (B) exposed to different concentrations of sanjuanolide.
FIGURE 6Measurement of the bacterial membrane potential of different treatments of S. aureus CMCC 26003 (A–D) and E. coli CMCC 44102 (E–H) as determined by flow cytometry. (A/E) CCCP+ and (B/F) CCCP−, (C/G) with 12.5 μg/ml sanjuanolide (D/H) and 25 μg/ml sanjuanolide.
FIGURE 7Ratio of red/green fluorescence intensities of S. aureus CMCC 26003 (A) and E. coli CMCC 44102 (B) under the different treatments, which were calculated using the MIF.